Phathom Pharmaceuticals sees FY26 net revenues $320M9$345M, consensus $312.56M

For the full year 2026, Phathom is providing the following financial guidance: Net revenues of $320-$345 million, which includes approximately $17-$20 million; Gross- to-net of 55-59%; Gross margin of approximately 80%; Non-GAAP operating expenses, excluding stock-based compensation, of $235-$250 million; Operating profitability, excluding stock-based compensation, expected beginning in the third quarter 2026 and for the full year 2026